Human FGF-19 Quantikine ELISA

Catalog # Availability Size / Price Qty
DF1900
Control Products Available
Human FGF-19 ELISA Standard Curve
2 Images
Product Details
Procedure
Citations (30)
FAQs
Supplemental Products
Reviews (4)

Human FGF-19 Quantikine ELISA Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (100 uL), Serum (100 uL), EDTA Plasma (100 uL), Heparin Plasma (100 uL)
Sensitivity
3.35 pg/mL
Assay Range
15.6 - 1,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
Specificity
Natural and recombinant human FGF-19
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference
No significant interference observed with available related molecules.

Product Summary

The Quantikine Human FGF-19 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human FGF-19 in cell culture supernates, serum, and plasma. It contains E. coli-expressed recombinant human FGF-19 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human FGF-19 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human FGF-19.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision

Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/mL) 113 346 689 119 349 700
Standard Deviation 7.26 15.7 24.8 6.46 19.3 31.7
CV% 6.4 4.5 3.6 5.5 5.5 4.5

Recovery

The recovery of FGF-19 spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 104 93-109
EDTA Plasma (n=4) 94 85-101
Heparin Plasma (n=4) 92 89-95
Serum (n=4) 95 88-100

Linearity

To assess the linearity of the assay, samples containing or spiked with high concentrations of FGF-19 were serially diluted with the Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human FGF-19 ELISA Linearity

Data Examples

Human FGF-19 ELISA Standard Curve

Product Datasheets

You must select a language.

x

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: FGF-19

The Fibroblast Growth Factor (FGF) family consists of at least 22 highly conserved proteins and are found in many species ranging from C. elegans and Drosophila to humans (1). FGFs are heparin-binding growth factors with a core 120 amino acid (aa) FGF domain that allows for a common tertiary structure. In general, FGFs are expressed during embryonic development and in restricted adult tissues. They act on cells of mesodermal and neuroectodermal origin to regulate diverse physiologic functions including angiogenesis, cell growth, pattern formation, metabolic regulation, cell migration, neurotrophic effects, and tissue repair (2). The activities of the FGF family are mediated by four receptors, FGF R1 through FGF R4 (2). The receptors are transmembrane proteins with a tyrosine kinase domain and are thought to act as classical receptor tyrosine kinases. FGF R5/FGF RL1 has also been described, but lacks the kinase domain and signaling capability (3). 

Human FGF-19 cDNA predicts a 251 aa precursor protein with a 22 aa signal peptide and a 229 aa secreted mature protein with no potential N-linked glycosylation sites (4, 5). It shares approximately 50% aa sequence identity with mouse and rat FGF-15 and 62% aa sequence identity with chicken FGF-19 (4-6). Unlike most FGFs, which bind to and activate more than one FGF receptor, FGF-19 appears to bind only FGF R4 (5). Receptor binding is capable of activating MAP Kinase and inducing the Prolactin promoter (7). FGF-19 has two putative disulfide bonds, one of which is conserved in the FGF family (8). Uniquely, it also has an extended loop structure that may affect heparan sulfate binding (8). 
The functional roles of FGF-19 continue to be elucidated and include developmental, metabolic, and tumorigenic activities. During chick embryogenesis, FGF-19 has been shown to act synergistically with Wnt-8c to initiate inner ear development (6). However, the mouse FGF-19 ortholog, FGF-15, is not required for this activity (9). FGF-19 is also expressed in the embryonic chicken eye where it may play a role in lens development (10). Questions regarding the functions of human FGF-19 have been addressed using ectopic expression. Transgenic over-expression of human FGF-19 in mice results in tumor formation, increased energy expenditure, decreased adiposity, and a resistance to weight gain in response to a high fat diet (11, 12). Similar affects have been observed in mice treated intravenously with recombinant FGF-19 (13).

Long Name:
Fibroblast Growth Factor 19
Entrez Gene IDs:
9965 (Human)
Alternate Names:
FGF19; FGF-19; fibroblast growth factor 19
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 100 µL Standard, Control, or Sample
  6.   Add 100 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
  7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours.
  10.   Aspirate and wash 4 times.

  11. 200 µL Substrate Solution
  12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.

  13. 50 µL Stop Solution
  14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human FGF-19 Quantikine ELISA

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

30 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics
    Authors: S Sydor, C Dandyk, J Schwerdt, P Manka, D Benndorf, T Lehmann, K Schallert, M Wolf, U Reichl, A Canbay, LP Bechmann, R Heyer
    International Journal of Molecular Sciences, 2022;23(16):.
    Species: Human
    Sample Types: Serum
  2. Suppression of Bile Acid Synthesis in a Preterm Infant Receiving Prolonged Parenteral Nutrition
    Authors: N Memon, CW Lee, A Herdt, BI Weinberger, T Hegyi, MO Carayannop, LM Aleksunes, GL Guo, IJ Griffin
    Journal of clinical and experimental hepatology, 2022;12(1):200-203.
    Species: Human
    Sample Types: Plasma
  3. Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass
    Authors: JY Guo, HH Chen, WJ Lee, SC Chen, SD Lee, CY Chen
    Nutrients, 2022;14(3):.
    Species: Human
    Sample Types: Plasma
  4. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells
    Authors: J Wang, H Zhao, L Zheng, Y Zhou, L Wu, Y Xu, X Zhang, G Yan, H Sheng, R Xin, L Jiang, J Lei, J Zhang, Y Chen, J Peng, Q Chen, S Yang, K Yu, D Li, Q Xie, Y Li
    Theranostics, 2021;11(10):5045-5060.
    Species: Human
    Sample Types: Cell Culture Supernates
  5. Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis
    Authors: J Góralska, U Ra?ny, A Polus, A Dziewo?ska, A Gruca, A Zdzienicka, A Dembi?ska-, B Solnica, A Micek, M Kapusta, K S?owi?ska-, M Malczewska
    Nutrients, 2020;12(2):.
    Species: Human
    Sample Types: Plasma
  6. NTCP Deficiency Causes Gallbladder Abnormalities in Mouse and Human Beings
    Authors: F Mao, MX Wang, X Hou, Z Zhou, YY Yan, LJ Fang, Z Tan, WY Fang, T Liu, W He, C Li, XB Xie, SQ Lu, J Sui, F Wang, L Han, JS Wang, W Li
    Cell Mol Gastroenterol Hepatol, 2020;0(0):.
    Species: Human
    Sample Types: Serum
  7. Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn's disease
    Authors: A Wilson, A Almousa, WA Teft, RB Kim
    Sci Rep, 2020;10(1):1866.
    Species: Human
    Sample Types: Plasma
  8. Genetic variation in the farnesoid X-receptor predicts Crohn's disease severity in female patients
    Authors: A Wilson, Q Wang, AA Almousa, LE Jansen, YH Choi, UI Schwarz, RB Kim
    Sci Rep, 2020;10(1):11725.
    Species: Human
    Sample Types: Plasma
  9. Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes
    Authors: G Calderon, A McRae, J Rievaj, J Davis, I Zandvakili, S Linker-Nor, D Burton, G Roberts, F Reimann, B Gedulin, A Vella, NF LaRusso, M Camilleri, FM Gribble, A Acosta
    EBioMedicine, 2020;55(0):102759.
    Species: Human
    Sample Types: Cell Culture Supernates
  10. Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes
    Authors: WS Liu, MJ Tang, TL Xu, JB Su, XQ Wang, F Xu, DM Zhang, Q Zhu, J Cao, H Wang
    Diabetol Metab Syndr, 2020;12(0):44.
    Species: Human
    Sample Types: Serum
  11. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
    Authors: AE O'Mara, JW Johnson, JD Linderman, RJ Brychta, S McGehee, LA Fletcher, YA Fink, D Kapuria, TM Cassimatis, N Kelsey, C Cero, Z Abdul-Sate, F Piccinini, AS Baskin, BP Leitner, H Cai, CM Millo, W Dieckmann, M Walter, NB Javitt, Y Rotman, PJ Walter, M Ader, RN Bergman, P Herscovitc, KY Chen, AM Cypess
    J. Clin. Invest., 2020;0(0):.
    Species: Human
    Sample Types: Plasma
  12. Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
    Authors: MJ Tang, JB Su, TL Xu, XQ Wang, DM Zhang, XH Wang
    Diabetol Metab Syndr, 2019;11(0):79.
    Species: Human
    Sample Types: Serum
  13. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study
    Authors: RN Appleby, I Moghul, S Khan, M Yee, P Manousou, TD Neal, JRF Walters
    PLoS ONE, 2019;14(1):e0211348.
    Species: Human
    Sample Types: Serum
  14. Divergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humans
    Authors: T Morville, RE Sahl, SA Trammell, JS Svenningse, MP Gillum, JW Helge, C Clemmensen
    JCI Insight, 2018;3(15):.
    Species: Human
    Sample Types: Plasma
  15. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver
    Authors: G Cui, RC Martin, H Jin, X Liu, H Pandit, H Zhao, L Cai, P Zhang, W Li, Y Li
    J. Exp. Clin. Cancer Res., 2018;37(1):136.
    Species: Human
    Sample Types: Cell Culture Supernates
  16. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis
    Authors: S Al-Dury, A Wahlström, S Wahlin, J Langedijk, RO Elferink, M Ståhlman, HU Marschall
    Sci Rep, 2018;8(1):6658.
    Species: Human
    Sample Types: Plasma
  17. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma
    Authors: L Gao, L Lang, X Zhao, C Shay, AY Shull, Y Teng
    Oncogene, 2018;0(0):.
    Species: Human
    Sample Types: Whole Cells
  18. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial
    Authors: D Friedrich, HU Marschall, F Lammert
    BMC Gastroenterol, 2018;18(1):76.
    Species: Human
    Sample Types: Serum
  19. Diet1, bile acid diarrhea, and FGF15/19: mouse model and human genetic variants
    Authors: JM Lee, JR Ong, L Vergnes, TQ de Aguiar, J Nolan, RM Cantor, JRF Walters, K Reue
    J. Lipid Res., 2018;0(0):.
    Species: Human
    Sample Types: Serum
  20. Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity
    Authors: S Straniero, F Rosqvist, D Edholm, H Ahlström, J Kullberg, M Sundbom, U Risérus, M Rudling
    J. Intern. Med, 2017;0(0):.
    Species: Human
    Sample Types: Serum
  21. Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome
    Authors: N Valentin, M Camilleri, P Carlson, SC Harrington, D Eckert, J O'Neill, D Burton, J Chen, AL Shaw, A Acosta
    Physiol Rep, 2017;5(5):.
    Species: Human
    Sample Types: Serum
  22. Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery
    Authors: L Martinez d, I Kyrou, J Vrbikova, V Hainer, P Sramkova, M Fried, MK Piya, S Kumar, G Tripathi, PG McTernan
    BMC Med, 2017;15(1):34.
    Species: Human
    Sample Types: Serum
  23. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
    PLoS ONE, 2016;11(5):e0151829.
    Species: Human
    Sample Types: Serum
  24. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.
    Authors: Natalia Gomez-Ospi, Carol J Potter, Rui Xiao, Kandamurugu Manickam, Mi-Sun Kim, Kang Ho Kim, Benjamin L Shneider, Jennifer L Picarsic, Theodora A Jacobson, Jing Zhang, Weimin He, Pengfei Liu, A S Knisely, Milton J Finegold, Donna M Muzny, Eric Boerwinkl, James R Lupski, Sharon E Plon, Richard A Gibbs, Christine M Eng, Yaping Yang, Gabriel C Washingto, Matthew H Porteus, William E Berquist, Neeraja Kambham, Ravinder J Singh, Fan Xia, Gregory M Enns, David D Moore
    Nature Communications, 2016;0(0):2041-1723.
    Species: Human
    Sample Types: Serum
  25. Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial
    Sci Rep, 2016;6(0):30173.
    Species: Human
    Sample Types: Plasma
  26. Modulation of fibroblast growth factor 19 expression by bile acids, meal replacement and energy drinks, milk, and coffee.
    Authors: Styer, Amanda M, Roesch, Stephen, Argyropoulos, George
    PLoS ONE, 2014;9(1):e85558.
    Species: Human
    Sample Types: Cell Culture Supernates
  27. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression.
    Authors: Feng S, Dakhova O, Creighton C, Ittmann M
    Cancer Res, 2013;73(8):2551-62.
    Species: Human
    Sample Types: Cell Culture Supernates
  28. Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history.
    Authors: Wang D, Zhu W, Li J, An C, Wang Z
    PLoS ONE, 2013;8(11):e81190.
    Species: Human
    Sample Types: Serum
  29. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control.
    Authors: Pournaras, Dimitri, Glicksman, Clare, Vincent, Royce P, Kuganolipava, Shophia, Alaghband-Zadeh, Jamie, Mahon, David, Bekker, Jan H R, Ghatei, Mohammad, Bloom, Stephen, Walters, Julian R, Welbourn, Richard, le Roux, Carel W
    Endocrinology, 2012;153(8):3613-9.
    Species: Human
    Sample Types: Plasma
  30. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression.
    Authors: Song KH, Li T, Owsley E
    Hepatology, 2009;49(1):297-305.
    Species: Human
    Sample Types: Cell Culture Supernates

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs

Reviews for Human FGF-19 Quantikine ELISA

Average Rating: 5 (Based on 4 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human FGF-19 Quantikine ELISA?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human FGF-19 Quantikine ELISA
By Anonymous on 11/25/2022
Sample Tested: Serum

Human FGF-19 Quantikine ELISA Kit
By Anonymous on 12/01/2017
Sample Tested: 2120Ep human embryonal carcinoma cell line

Human FGF-19 Quantikine ELISA Kit
By Jessica Fernando on 10/23/2017
Sample Tested: EDTA Plasma

solid assay


Human FGF-19 Quantikine ELISA Kit
By Mousumi Chaudhury on 09/30/2016
Sample Tested: pig serum

it was quick, easy and clear result. standards gave well standard curve, quite sensitive